Search Result

Results for "

ROS Kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Reactive Oxygen Species (ROS) (40) ROS Kinase (13) Acetyl-CoA Carboxylase (2) Akt (8) AMPK (5) Amyloid-β (2) Anaplastic lymphoma kinase (ALK) (7) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (35) ATP Synthase (1) Autophagy (5) Bacterial (5) Bcl-2 Family (6) Bcr-Abl (3) BCRP (1) c-Myc (2) Calcium Channel (1) Cannabinoid Receptor (1) Casein Kinase (1) Caspase (9) CDK (4) Checkpoint Kinase (Chk) (1) Cholinesterase (ChE) (1) Creatine Kinase (1) DNA/RNA Synthesis (1) Drug Derivative (2) DYRK (2) EGFR (5) Epigenetic Reader Domain (1) ERK (4) Ferroptosis (4) FGFR (1) FLT3 (2) Fungal (2) FXR (1) Glutathione Peroxidase (1) Glycosidase (1) GSK-3 (2) HSV (2) IGF-1R (2) iGluR (1) IKK (1) Influenza Virus (1) Interleukin Related (2) JAK (2) JNK (5) Keap1-Nrf2 (1) MDM-2/p53 (1) MEK (2) Microtubule/Tubulin (2) Mitochondrial Metabolism (4) Mixed Lineage Kinase (1) Monoamine Oxidase (1) mTOR (4) Necroptosis (1) NF-κB (6) NKCC (1) NO Synthase (1) NOD-like Receptor (NLR) (5) p38 MAPK (3) Parasite (3) PARP (6) PDGFR (2) PDHK (1) PDK-1 (1) PERK (1) Phosphatase (1) PI3K (2) PKA (7) PKC (5) Polo-like Kinase (PLK) (1) Pyruvate Kinase (3) Reference Standards (6) RET (1) Ribosomal S6 Kinase (RSK) (1) RIP kinase (1) Ser/Thr Kinase (1) Sirtuin (1) Src (4) STAT (6) Stearoyl-CoA Desaturase (SCD) (2) TNF Receptor (2) Topoisomerase (1) Trk Receptor (1) VEGFR (5) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (52) Cardiovascular Disease (4) Endocrinology (1) Infection (11) Inflammation/Immunology (18) Metabolic Disease (11) Neurological Disease (16)

By Targets:

Reactive Oxygen Species (ROS) (40)

ROS Kinase (13)

Acetyl-CoA Carboxylase (2)

Akt (8)

AMPK (5)

Amyloid-β (2)

Anaplastic lymphoma kinase (ALK) (7)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (35)

ATP Synthase (1)

Autophagy (5)

Bacterial (5)

Bcl-2 Family (6)

Bcr-Abl (3)

BCRP (1)

c-Myc (2)

Calcium Channel (1)

Cannabinoid Receptor (1)

Casein Kinase (1)

Caspase (9)

CDK (4)

Checkpoint Kinase (Chk) (1)

Cholinesterase (ChE) (1)

Creatine Kinase (1)

DNA/RNA Synthesis (1)

Drug Derivative (2)

DYRK (2)

EGFR (5)

Epigenetic Reader Domain (1)

ERK (4)

Ferroptosis (4)

FGFR (1)

FLT3 (2)

Fungal (2)

FXR (1)

Glutathione Peroxidase (1)

Glycosidase (1)

GSK-3 (2)

HSV (2)

IGF-1R (2)

iGluR (1)

IKK (1)

Influenza Virus (1)

Interleukin Related (2)

JAK (2)

JNK (5)

Keap1-Nrf2 (1)

MDM-2/p53 (1)

MEK (2)

Microtubule/Tubulin (2)

Mitochondrial Metabolism (4)

Mixed Lineage Kinase (1)

Monoamine Oxidase (1)

mTOR (4)

Necroptosis (1)

NF-κB (6)

NKCC (1)

NO Synthase (1)

NOD-like Receptor (NLR) (5)

p38 MAPK (3)

Parasite (3)

PARP (6)

PDGFR (2)

PDHK (1)

PDK-1 (1)

PERK (1)

Phosphatase (1)

PI3K (2)

PKA (7)

PKC (5)

Polo-like Kinase (PLK) (1)

Pyruvate Kinase (3)

Reference Standards (6)

RET (1)

Ribosomal S6 Kinase (RSK) (1)

RIP kinase (1)

Ser/Thr Kinase (1)

Sirtuin (1)

Src (4)

STAT (6)

Stearoyl-CoA Desaturase (SCD) (2)

TNF Receptor (2)

Topoisomerase (1)

Trk Receptor (1)

VEGFR (5)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (52)

Cardiovascular Disease (4)

Endocrinology (1)

Infection (11)

Inflammation/Immunology (18)

Metabolic Disease (11)

Neurological Disease (16)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Antibodies

GMP Molecules

Targets Recommended: ROS Kinase Reactive Oxygen Species (ROS)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0764

Bucladesine sodium Maximum Cited Publications 41 Publications Verification Dibutyryl cAMP sodium; DBcAMP sodium	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial *ROS* formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-Y0445A

Sodium dichloroacetate 25+ Cited Publications	PDK-1 NKCC PDHK Reactive Oxygen Species (ROS) Apoptosis	Cancer
Sodium dichloroacetate is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor. Sodium dichloroacetate also stimulates pyruvate dehydrogenase (PDH) activity and works as a Na ⁺-K ⁺-2Cl ⁻ cotransporter (NKCC) inhibitor. Sodium dichloroacetate prevents the phosphorylation of the E1α subunit of PDC, promoting the entry of pyruvate into the mitochondria for oxidative metabolism, reducing lactate production, and simultaneously increasing the production of reactive oxygen species (ROS). Sodium dichloroacetate inhibits tumor cell proliferation and induces apoptosis. Sodium dichloroacetate is promising for research of cancers .

HY-B0481

Miglitol 2 Publications Verification BAY1099; BAY-m1099	Glycosidase AMPK Reactive Oxygen Species (ROS)	Metabolic Disease
Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets .

HY-N0281

Daphnetin Maximum Cited Publications 7 Publications Verification 7,8-Dihydroxycoumarin	EGFR PKA PKC Autophagy Apoptosis AMPK Akt mTOR Reactive Oxygen Species (ROS) Caspase Bcl-2 Family PARP Parasite	Cardiovascular Disease Inflammation/Immunology Cancer
Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC₅₀s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1β, ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research .

HY-B0764A

Bucladesine hemicalcium Maximum Cited Publications 41 Publications Verification Dibutyryl cAMP hemicalcium; DBcAMP hemicalcium	PKA Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) hemicalcium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial *ROS* formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-13326

ASP3026 5+ Cited Publications	Anaplastic lymphoma kinase (ALK) Apoptosis ROS Kinase Caspase PARP IGF-1R STAT Akt JNK	Cancer
ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC₅₀ value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited *ROS* and ACK. ASP3026 can be used in anti-tumor research .

HY-136409

N-Decanoyl-L-homoserine lactone C10-HSL	Bacterial Reactive Oxygen Species (ROS)	Infection
N-decanoyl-L-homoserine lactone (C10-HSL) is a N-acyl-homoserine lactone (AHL) N-decanoyl-L-homoserine lactone can inhibit primary root growth in Arabidopsis. N-decanoyl-L-homoserine lactone triggers a transient and immediate increase in the concentrations of cytosolic free Ca ²⁺ and reactive oxygen species (ROS), increases the activity of mitogen-activated protein kinase 6 (MPK6), and induces nitric oxide (NO) production in Arabidopsis roots .

HY-N0712

Typhaneoside 3 Publications Verification	Autophagy mTOR Akt FXR	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Typhaneoside is an orally bioavailable signal modulator and cellular regulator. Typhaneoside regulates the PI3K/Akt/mTOR autophagy transduction pathway. Typhaneoside promotes the activation of AMP-activated protein kinase and Caspase-3, induces apoptosis, ferroptosis, autophagy, ROS accumulation, and cell cycle arrest at the G₂/M phase, and reduces cancer cell viability. Typhaneoside activates the farnesoid X receptor signaling pathway, improves glucose and lipid metabolism, alleviates inflammatory responses, oxidative stress and hepatic lipid accumulation, and exerts hepatoprotective effects. Typhaneoside is applicable to research related to post-myocardial infarction heart failure, acute myeloid leukemia, non-alcoholic fatty liver disease, and neurological disorders .

HY-112356

Scytonemin	Apoptosis Reactive Oxygen Species (ROS) Polo-like Kinase (PLK)	Inflammation/Immunology Cancer
Scytonemin is a hydrophobic alkaloid pigment that can be isolated from the outer sheath of cyanobacteria. Scytonemin has protective function against short-wave solar ultraviolet (UV) radiation, which can reduce the generation of reactive oxygen species (ROS) and the formation of DNA damage. Scytonemin also has anti-inflammatory and anti-proliferative activities, produces concentration-dependent inhibition (IC₅₀=2.0 μM) of polo-like kinase 1 (PLK1)-mediated cdc25C phosphorylation, and plays an important role in regulating the G2/M transition in the cell cycle. It can be used in the research of cancer, acute inflammation and sunscreen cosmetics .

HY-117049

Leucettine L41 1 Publications Verification	DYRK CDK GSK-3 Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) and CDC-like kinases (CLKs). Leucettine L41 can also inhibit GSK-3 singnaling. Leucettine L41 can inhibit cell apoptosis and *ROS* production. Leucettine L41 can promote β-cell cell cycle progression, cell proliferation and increase insulin secretion. Leucettine L41 can be used for the researches of neurological disease and metabolic disease, such as Alzheimer’s disease (AD) and diabetes .

HY-N0701

(-)-Asarinin 1 Publications Verification	Apoptosis Reactive Oxygen Species (ROS) STAT Src Stearoyl-CoA Desaturase (SCD) Bacterial	Infection Neurological Disease Inflammation/Immunology Cancer
(-)-Asarinin is a tetrahydrofurofurano lignan with various biological activities. (-)-Asarinin induces apoptosis in cancer cells. (-)-Asarinin promotes mitochondrial *ROS* accumulation, inhibits the STAT3 signaling pathway and induces apoptosis in precancerous cells. (-)-Asarinin is a Src family kinase inhibitor that suppresses mast cell activation. (-)-Asarinin is a non-competitive Δ5-desaturase inhibitor with a K_i of 0.28 mM. (-)-Asarinin possesses pain relief, anti-viral, anti-allergic and anti-tuberculous bacilli, and anti-tumor effects .

HY-111380

EHT 1610 2 Publications Verification	DYRK	Neurological Disease
EHT 1610 is a potent inhibitor of DYRK, with IC₅₀s of 0.36 nM (DYRK1A), 0.59 nM (DYRK1B), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis ^- .

HY-N0818

Chikusetsusaponin Iva 2 Publications Verification Calenduloside F	Keap1-Nrf2	Infection Metabolic Disease Endocrinology Cancer
Chikusetsusaponin IVa is an orally active protein kinase activator. Chikusetsusaponin IVa binds to YAP with a K_D value of 0.388 mM. Chikusetsusaponin IVa reduces inflammatory mediators (IL-6, IL-10, COX-2) expression, NO production, promotes *ROS* generation, induces Apoptosis, inhibits MAPK, TAZ, and regulates Nrf2, JAK/STAT. Chikusetsusaponin Iva has anti-H9N2 AIV and anti-endometrial cancer activities. Chikusetsusaponin Iva shows anti-inflammatory, hepatoprotective and osteoprotective effects .

HY-N5063

Plantainoside D 2 Publications Verification	Angiotensin-converting Enzyme (ACE) IKK Calcium Channel PKC Reactive Oxygen Species (ROS) NF-κB Apoptosis Sirtuin NOD-like Receptor (NLR)	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Plantainoside D, a phenylethanoid glycosides, is a IKK-β inhibitor with diverse biological activities. Plantainoside D shows inhibitory activity of angiotensin-converting enzyme (ACE) with an IC₅₀ of 2.17 mM. Plantainoside D significantly reduces the release of glutamate from nerve terminals in the cerebral cortex of rats by inhibiting the voltage-dependent calcium channel (VDCCs) and protein kinase C (PKC) signaling cascade. Plantainoside D significantly alleviates cell apoptosis by inhibiting the generation of *ROS* and the activation of NF-κB. Plantainoside D significantly improves acute lung injury (ALI) induced by sepsis by regulating the Sirt3/NLRP3 signaling pathway. Plantainoside D can be used for the study of neuroprotection, antioxidant, anti-inflammation, antihypertension .

HY-111237

Butyrolactone I Olomoucin	CDK NF-κB PERK Bcl-2 Family Reactive Oxygen Species (ROS) Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Butyrolactone I is an orally active and ATP-competitive inhibitor of CDK1. Butyrolactone I inhibits NF-κB, cdc2 kinase, Bax, *ROS* production, modulates the PERK/CHOP. Butyrolactone I mitigates heat-stress-induced Apoptosis. Butyrolactone I shows anti-inflammatory and intestinal protective activity. Butyrolactone I has antitumor effects against non-small cell lung, small cell lung, prostate cancer and leukemia. Butyrolactone I can be used in NASH research .

HY-N0772

Isomangiferin 4 Publications Verification	VEGFR NOD-like Receptor (NLR) NF-κB Bacterial AMPK Acetyl-CoA Carboxylase Apoptosis Reactive Oxygen Species (ROS) HSV Drug Derivative	Infection Metabolic Disease Inflammation/Immunology Cancer
Isomangiferin is an orally active xanthone C-glucoside, and its chemical structure is similar to Mangiferin (HY-N0290). Isomangiferin is an effective VEGFR-2 kinase inhibitor, which can induces cell apoptosis, inhibit the growth, metastasis and angiogenesis of breast cancer. Isomangiferin exerts anti-inflammatory effects by inhibiting the HMGB1/NLRP3/NF-κB signaling pathway, thereby improving the renal function indicators of diabetic mice. Isomangiferin exhibits inhibitory effects on various bacteria and herpes simplex virus type 1 (HSV-1). Isomangiferin promotes the migration and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduces cell apoptosis and the production of *ROS* by activating the AMPK/ACC pathway, thereby facilitating fracture healing .

HY-N0442

5-O-Methylvisammioside 4'-O-β-D-Glucosyl-5-O-methylvisamminol	NF-κB p38 MAPK JNK Src TNF Receptor NOD-like Receptor (NLR) Amyloid-β MEK ERK Ferroptosis VEGFR Anaplastic lymphoma kinase (ALK) Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
5-O-Methylvisammioside (4'-O-β-D-Glucosyl-5-O-methylvisamminol) is an orally active natural chromone glycoside and multiple biological activities. 5-O-Methylvisammioside inhibits ferroptosis by activating the Nrf2/HO-1 signaling axis. 5-O-Methylvisammioside alleviates intestinal barrier damage by inhibiting the *ROS/NF-κB/NLRP3* pathway. 5-O-Methylvisammioside exerts a protective effect against acute liver injury by reducing ALT/AST, decreasing inflammatory infiltration, and inhibiting IκB-α phosphorylation and NF-κB nuclear translocation. 5-O-Methylvisammioside blocks the HMGB1/RAGE/MEK/ERK signaling axis to exert anti-tumor and anti-angiogenic effects. 5-O-Methylvisammioside improves depression-like behaviors by inhibiting Src kinase and the NF-κB pathway .

HY-103275

Adaphostin NSC 680410	Bcr-Abl Apoptosis	Cancer
Adaphostin (NSC 680410), the adamantyl ester of AG957, is a potent p210 ^bcr/abl inhibitor (IC₅₀=14 μM). Adaphostin induces apoptosis in T-lymphoblastic human leukemia cell lines (IC₅₀ ranging from 17 to 216 nM). Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Adaphostin increased the level of reactive oxygen species (ROS) within CLL B cells .

HY-124833

Quinalizarin	Casein Kinase Apoptosis Fungal Reactive Oxygen Species (ROS) Caspase MDM-2/p53 PARP Bcl-2 Family Akt ERK STAT JNK p38 MAPK CDK	Infection Cancer
Quinalizarin is a protein kinase CK2 inhibitor with a K_i of 0.052 μM. Quinalizarin exhibits antifungal and anticancer activities. Quinalizarin induces *ROS* production, apoptotic signaling, mitochondrial pathway activation, cell cycle arrest, and cytotoxicity in cancer cells. Quinalizarin inhibits hyphal growth, biofilm formation, and mature biofilm integrity of Candida albicans. Quinalizarin can be used in research related to cancer and fungal infections .

HY-N2902

Artocarpin	Reactive Oxygen Species (ROS)	Cancer
Artocarpin is an orally active apoptosis inducer. Artocarpin targets NF-κB, Erk1/2, p38 MAPK, AktS473, p53, Akt 1 kinase and Akt 2 kinase. Artocarpin induces reactive oxygen species (ROS) production, mediates p53-dependent and p53-independent apoptotic signaling pathways, induces G1-phase cell cycle arrest, and triggers autophagic cell death. Artocarpin exerts cytotoxic and bactericidal effects on cancer cells, reduces bacterial load, and exhibits anti-inflammatory, analgesic and anti-angiogenic activities .

HY-N1745A

3-Deoxysappanchalcone 2 Publications Verification	Influenza Virus	Infection Inflammation/Immunology Cancer
3-Deoxysappanchalcone is a kinase inhibitor and antiviral agent. 3-Deoxysappanchalcone directly targets MET, EGFR, AKT, mTOR, p38 MAPK, JNK, thrombin, FXa, and influenza virus neuraminidase, thereby regulating related signaling pathways. 3-Deoxysappanchalcone induces cell cycle arrest, ROS production, and apoptosis. 3-Deoxysappanchalcone exhibits anti-inflammatory, anti-allergic, anticoagulant, and antithrombotic activities. 3-Deoxysappanchalcone is applicable to research related to gefitinib-resistant lung cancer, esophageal squamous cell carcinoma, thrombosis, and influenza virus infection .

HY-123450

S116836	Bcr-Abl Apoptosis PDGFR	Cancer
S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies . S116836 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B0764B

Bucladesine Dibutyryl cAMP; DBcAMP	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial *ROS* formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-B0764G

Bucladesine sodium Dibutyryl cAMP sodium; DBcAMP sodium	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (GMP) is a Bucladesine sodium (HY-B0764) produced by using GMP guidelines. Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial *ROS* formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-N11003

Vanicoside A 1 Publications Verification	PKC Reactive Oxygen Species (ROS)	Cancer
Vanicoside A is a phenylpropanoid glycoside. Vanicoside A can be isolated from Polygonum pensylvanicum. Vanicoside A inhibits *protein kinase* C (PKC), induces substantial ROS** production. Vanicoside A exhibits anticancer activity against melanoma .

HY-B0764R

Bucladesine sodium (Standard) Dibutyryl cAMP sodium (Standard); DBcAMP sodium (Standard)	Reference Standards PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (Standard) is the analytical standard of Bucladesine sodiumn (HY-B0764). This product is intended for research and analytical applications. Bucladesine is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial *ROS* formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-W134163

(E)-2-Octenal trans-2-Octenal	Fungal Reactive Oxygen Species (ROS) Mitochondrial Metabolism Phosphatase Pyruvate Kinase	Infection
(E)-2-Octenal is an Antifungal agent. (E)-2-Octenal disrupts cell membrane integrity and causes *ROS* accumulation. (E)-2-Octenal decreases the activities of phosphofructokinase and pyruvate kinase. (E)-2-Octenal inhibits Neofusicoccum parvum growth by disrupting mitochondrial energy metabolism. (E)-2-Octenal suppresses the growth of a Prochloraz (HY-B0845)-resistant Penicillium italicum strain. (E)-2-octenal exerts a broad-spectrum and potent inhibitory effect on various fungi, including Sclerotium rolfsii, Metarhizium anisopliae sensu lato, and Aspergillus flavus, etc. (E)-2-Octenal can be used for the research of citrus blue mold and mango stem-end rot .

HY-178163

Zharp1-163	Ferroptosis Necroptosis RIP kinase Reactive Oxygen Species (ROS) Mixed Lineage Kinase	Inflammation/Immunology
Zharp1-163 is a dual inhibitor of ferroptosis and necroptosis. Zharp1-163 effectively blocks ferroptosis by reducing reactive oxygen species (ROS) levels and inhibits necroptosis by potently and selectively targeting RIPK1 kinase activity (K_D = 240 nM; IC₅₀ = 406.1 nM). Zharp1-163 inhibits the cellular activation of RIPK1, RIPK3 and MLKL in response to necroptotic stimulation. Zharp1-163 markedly attenuates TNF-α (HY-P1875)-induced systemic inflammatory syndrome, including the prevention of TNF-α-induced mortality and hypothermia in mice. Zharp1-163 significantly alleviates acute kidney injury associated with both necroptosis and ferroptosis in models induced by Cisplatin (HY-17394) and ischemia-reperfusion. Zharp1-163 can be used for the study of diseases associated with cell death pathways, such as kidney disease .

HY-148228

ROS kinases-IN-1	ROS Kinase	Cancer
ROS kinases-IN-1 (pag 98) is a **ROS tyrosine kinase inhibitor with IC₅₀** value of 1.22 μM. ROS kinases-IN-1 shows anti-tumor activity .

HY-160172

ALK/ROS1-IN-4	Anaplastic lymphoma kinase (ALK) ROS Kinase	Cancer
ALK/ROS1-IN-4 (example 13) is a dual inhibitor of ALK and **ROS1 kinase** .

HY-N0281R

Daphnetin (Standard) 7,8-Dihydroxycoumarin (Standard)	Reference Standards EGFR PKA PKC Autophagy Apoptosis AMPK Akt mTOR Reactive Oxygen Species (ROS) Caspase Bcl-2 Family PARP Parasite	Inflammation/Immunology Cancer
Daphnetin (Standard) is the analytical standard of Daphnetin. This product is intended for research and analytical applications. Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC₅₀s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1 , ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research .

HY-150537

AChE/GSK-3β-IN-1	Cholinesterase (ChE) GSK-3 Microtubule/Tubulin ROS Kinase	Neurological Disease
AChE/GSK-3β-IN-1 (compound GT15) is a potent, dual AChE/GSK-3β inhibitor with IC₅₀ values of 1.2, 149.8 and 22.4 nM for hAChE , hBChE and hGSK-3β, respectively. AChE/GSK-3β-IN-1 penetrates the blood-brain barrier (BBB). AChE/GSK-3β-IN-1 has high kinase selectivity profiles for the CMGC kinase family. AChE/GSK-3β-IN-1 occupies the ATP binding site of DYRK1A. AChE/GSK-3β-IN-1 inhibits ROS expression and reduces oxidative stress. AChE/GSK-3β-IN-1 can be used for Alzheimer’s disease research .

HY-178441

PKM2-IN-11	Pyruvate Kinase Reactive Oxygen Species (ROS) Apoptosis Microtubule/Tubulin	Metabolic Disease Cancer
PKM2-IN-11 is a PKM2 inhibitor (IC₅₀ = 0.363 μM). PKM2-IN-11 has dual mechanisms involving pyruvate kinase M2 (PKM2) inhibition and microtubule stabilization. PKM2-IN-11 can decrease PKM2 protein levels in MCF-7 cells. PKM2-IN-11 can slightly reduce reactive oxygen species (ROS) levels and significantly increase early apoptotic cells. PKM2-IN-11 induces G2/M phase arrest. PKM2-IN-11 can be used for the study of breast cancer .

HY-178448

EGFR-IN-178	EGFR JAK Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Cannabinoid Receptor Glutathione Peroxidase Caspase	Inflammation/Immunology Cancer
EGFR-IN-178 is an orally active EGFR mutant inhibitor, exhibits highly selective inhibitory activity against mutants of the EGFR enzyme, including Del19 (IC₅₀ = 3.4 nM), L858R/T790 M (IC₅₀ = 2.9 nM), and Del19/T790 M (IC₅₀ = 2.5 nM). EGFR-IN-178 has good activity against JAK2 (IC₅₀ = 55.6 nM) and JAK3 (IC₅₀ = 46.1 nM) kinases. EGFR-IN-178 can increase cellular lipid oxide MDA, meanwhile decrease GSH content, causing ferroptosis in cancer cells. EGFR-IN-178 promotes apoptosis by increasing cleaved caspase-3 expression. EGFR-IN-178 can inhibit the phosphorylation of EGFR protein and decrease the active form p-JAK2 for JAK2, induce an increase in intracellular *ROS*. EGFR-IN-178 can be used for the study of non-small cell lung cancer (NSCLC) .

HY-148314

ROS kinases-IN-2	ROS Kinase	Cancer
ROS kinases-IN-2 is a *ROS* kinase inhibitor. ROS kinases-IN-2 can be used for research on stomach cancer, liver cancer and colorectal cancer .

HY-150974

ROS1-IN-1	ROS Kinase	Cancer
ROS1-IN-1 (Compound 31) is a potent and selective *ROS1* kinase inhibitor with an IC₅₀ of 0.097 μM .

HY-160172A

ALK/ROS1-IN-4 hydrate	Anaplastic lymphoma kinase (ALK) ROS Kinase	Cancer
ALK/ROS1-IN-4 (hydrate) (example 13) is a dual inhibitor of ALK and **ROS1 kinase** .

HY-153743

*Protein kinase* inhibitor 4**	ROS Kinase Trk Receptor	Cancer
Protein kinase inhibitor 4 (Compound 3) is a protein kinase inhibitor that inhibits TRK-A and *ROS1* (IC₅₀=3.0 nM and 104 nM respectively) .

HY-161975

ROS1-IN-2	ROS Kinase	Cancer
ROS1-IN-2 (Compound 3) is a ROS1 inhibitor. ROS1-IN-2 can be used in the study of cancer .

HY-E70729

ICK Recombinant Human Active Protein Kinase	Ser/Thr Kinase	Metabolic Disease
The intestinal cell kinase (ICK) protein belongs to the ros-cross hybridizing kinase (RCK) family. ICK is a ciliary protein, involved in ciliogenesis and regulation of intraflagellar transport (IFT). ICK Recombinant Human Active Protein Kinase is a recombinant ICK protein that can be used to study ICK-related functions .

HY-170418

ALK/ROS1-IN-5	Anaplastic lymphoma kinase (ALK) ROS Kinase Apoptosis	Cancer
ALK/ROS1-IN-5 (compound X4) is a selective ALK and *ROS1* kinases inhibitor with IC₅₀s of 0.512 μM (ALK), 0.766 μM (ROS1), respectively. ALK/ROS1-IN-5 inhibits H2228 cells with an IC₅₀ of 0.034 μM. ALK/ROS1-IN-5 induces cancer cells apoptosis in dose-dependent manner. ALK/ROS1-IN-5 effectively suppresses the expression of p-ALK and p-ERK in cancer cells_[1].

HY-103275R

Adaphostin (Standard) NSC 680410 (Standard)	Reference Standards Bcr-Abl Apoptosis	Cancer
Adaphostin (Standard) is the analytical standard of Adaphostin. This product is intended for research and analytical applications. Adaphostin (NSC 680410), the adamantyl ester of AG957, is a potent p210bcr/abl inhibitor (IC50=14 μM). Adaphostin induces apoptosis in T-lymphoblastic human leukemia cell lines (IC50 ranging from 17 to 216 nM). Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Adaphostin increased the level of reactive oxygen species (ROS) within CLL B cells .

HY-13326R

ASP3026 (Standard)	Anaplastic lymphoma kinase (ALK) Apoptosis ROS Kinase Caspase PARP IGF-1R STAT Akt JNK	Cancer
ASP3026 (Standard) is the analytical standard of ASP3026. This product is intended for research and analytical applications. ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC50 value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research .

HY-111125

AMRI-59	Parasite Reactive Oxygen Species (ROS) Apoptosis	Infection Cancer
AMRI-59 is a potent inhibitor of PrxI used for parasitic infections. AMRI-59 can increase cellular *ROS, leading to activation of signaling pathways mediated by mitochondria and apoptosis signal-regulated kinase* 1, thereby leading to apoptosis in A549 human lung adenocarcinoma. AMRI-59 exhibits significant antitumor activity without apparent acute toxicity .

HY-156092

Antitumor photosensitizer-4	BCRP Apoptosis	Cancer
Antitumor photosensitizer-4 (compound 10b) is a potent tyrosine kinase inhibitor (TKI) targeting ABCG2. Antitumor photosensitizer-4 is a photosensitizer (PS) consisting of a conjugate of dasatinib (HY-10181) and imatinib (HY-15463). Antitumor photosensitizer-4 induces apoptosis and ROS production and exhibits strong phototoxicity to HepG2 and B16-F10 cells .

HY-123597

NSC 109555 DDUG; NCI C04808	Autophagy Checkpoint Kinase (Chk)	Cancer
NSC 109555 is an ATP-competitive inhibitor of checkpoint kinase 2 (Chk2; IC₅₀=200 nM in a cell-free kinase assay). It is selective for Chk2 over Chk1 and 16 kinases in a panel but does inhibit Brk, c-Met, IGFR, and LCK with IC₅₀ values of 210, 6,000, 7,400, and 7,100 nM, respectively. NSC 109555 inhibits Chk2 autophosphorylation and phosphorylation of the Chk2 substrate histone H1 in vitro (IC₅₀=240 nM). It inhibits the growth of, and induces autophagy in, L1210 leukemia cells in vitro.2 NSC 109555 (1,250 nM) potentiates gemcitabine-induced cytotoxicity in MIA PaCa-2, CFPAC-1, PANC-1, and BxPC-3 pancreatic cancer cells, as well as reduces gemcitabine-induced increases in Chk2 phosphorylation and enhances gemcitabine-induced production of reactive oxygen species (ROS) in MIA PaCa-2 cells.

HY-N0701R

(-)-Asarinin (Standard)	Reference Standards Apoptosis Reactive Oxygen Species (ROS) STAT Src Stearoyl-CoA Desaturase (SCD) Bacterial	Infection Neurological Disease Inflammation/Immunology Cancer
(-)-Asarinin (Standard) is the analytical standard of (-)-Asarinin (HY-N0701). This product is intended for research and analytical applications. (-)-Asarinin is a tetrahydrofurofurano lignan with various biological activities. (-)-Asarinin induces apoptosis in cancer cells. (-)-Asarinin promotes mitochondrial *ROS* accumulation, inhibits the STAT3 signaling pathway and induces apoptosis in precancerous cells. (-)-Asarinin is a Src family kinase inhibitor that suppresses mast cell activation. (-)-Asarinin is a non-competitive Δ5-desaturase inhibitor with a K_i of 0.28 mM. (-)-Asarinin possesses pain relief, anti-viral, anti-allergic and anti-tuberculous bacilli, and anti-tumor effects.

HY-155178

Antiproliferative agent-34	EGFR	Cancer
Antiproliferative agent-34 (Compound A14) is a multi-target kinase inhibitor, with an IC₅₀ of 177 nM and 1567 nM for EGFR L858R/T790M and EGFR WT. Antiproliferative agent-34 also inhibits JAK2, ROS1, FLT3, FLT4, PDGFRα with IC₅₀ of 30.93, 106.90, 108.00, 226.60, 42.53 nM. Antiproliferative agent-34 inhibits H1975 and HCC827 cells proliferation with IC₅₀ values below 40 nM under normoxic condition, and the anti-proliferation potency achieves 4–6-fold improvement (IC₅₀ values < 10 nM) under hypoxic condition .

HY-178029

RSK2/TOP2-IN-1	Ribosomal S6 Kinase (RSK) Topoisomerase Apoptosis Autophagy Reactive Oxygen Species (ROS)	Cancer
RSK2/TOP2-IN-1 is a RSK2/TOP2 dual inhibitor. RSK2/TOP2-IN-1 targets key tumor progression enzymes including ribosomal S6 kinase 2 and topoisomerases IIα/IIβ. RSK2/TOP2-IN-1 shows selectivity index > 2 against all squamous cell carcinoma (SCC) cell lines. RSK2/TOP2-IN-1 can induce cell apoptosis, autophagy and *ROS* production. RSK2/TOP2-IN-1 can be used for the research of cancer, such as squamous cell carcinoma .

HY-N0772R

Isomangiferin (Standard)	Reference Standards VEGFR NF-κB NOD-like Receptor (NLR) AMPK Acetyl-CoA Carboxylase Apoptosis Reactive Oxygen Species (ROS) HSV Drug Derivative	Infection Metabolic Disease Inflammation/Immunology Cancer
Isomangiferin (Standard) is the analytical standard of Isomangiferin (HY-N0772). This product is intended for research and analytical applications. Isomangiferin is an orally active xanthone C-glucoside, and its chemical structure is similar to Mangiferin (HY-N0290). Isomangiferin is an effective VEGFR-2 kinase inhibitor, which can induces cell apoptosis, inhibit the growth, metastasis and angiogenesis of breast cancer. Isomangiferin exerts anti-inflammatory effects by inhibiting the HMGB1/NLRP3/NF-κB signaling pathway, thereby improving the renal function indicators of diabetic mice. Isomangiferin exhibits inhibitory effects on various bacteria and herpes simplex virus type 1 (HSV-1). Isomangiferin promotes the migration and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduces cell apoptosis and the production of *ROS* by activating the AMPK/ACC pathway, thereby facilitating fracture healing.

Cat. No.	Product Name

HY-L075

Anti-Lung Cancer Compound Library

2,850 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 2,850 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P11600

SGNLTKYWKKIWKPGIKKWIK	Bacterial Reactive Oxygen Species (ROS) Interleukin Related DNA/RNA Synthesis	Infection
SGNLTKYWKKIWKPGIKKWIK is a thymidylate kinase (TMK)-targeting antimicrobial peptide with a K_D value of 4.721 μM. SGNLTKYWKKIWKPGIKKWIK exerts antimicrobial effects through multiple mechanisms, including membrane disruption, induction of *ROS, and DNA* binding. SGNLTKYWKKIWKPGIKKWIK shows remarkable activity against Gram-negative bacteria, possesses good biocompatibility, and rarely induces drug resistance. SGNLTKYWKKIWKPGIKKWIK can be used for research on Gram-negative bacterial infections .

Cat. No.	Product Name	Category	Target	Chemical Structure